Chinese researchers develop immunotherapeutic agent for colon cancer
Release time:2024-05-21 17:58:25
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for 。
TIANJIN, March 15 (Xinhua) -- Chinese researchers have developed a novel immunotherapeutic agent for treating colon cancer, according to a recent article in the academic journal ACS Nano. In animal experiments, the agent, upon successful entry into tumor cells, can enhance T cell effector function to kill tumor cells and suppress colon tumor growth, according to Lu Chunwan from the School of Life Sciences of Tianjin University, one of the authors of the article. The agent can enhance tumor immunogenicity and inhibit colon tumor growth, with no significant impact on normal cells, said Lu. Colon cancer, characterized by its long latency period and high mortality rate, poses a severe threat to human health. Among various therapies, immunotherapy is considered one of the most promising treatment directions, according to Lu.
(Editor:Fu Bo)
Related articles
Liverpool confirms Arne Slot as Jurgen Klopp's replacement
Arne Slot will take on one of the most daunting challenges in soccer by replacing Jurgen Klopp as Li2024-05-21Explainer: What to expect from AU summit as education, development take center stage
ADDIS ABABA, Feb. 17 (Xinhua) -- As African leaders gather at the headquarters of the African Union2024-05-21China has favorable conditions for overall price stability
People buy fruits and vegetables at a supermarket in Changchun, northeast China's Jilin Province, Ma2024-05-21Market for African Performing Arts of Abidjan held in Cote d'Ivoire
Dancers perform at the opening of the Market for African Performing Arts of Abidjan, a cultural even2024-05-21Verona confirms Serie A status for another year after beating Salernitana
SALERNO, Italy (AP) — Verona secured a place in next year’s Serie A after beating Salernitana 2-1 on2024-05-21- HARARE, April 14 (Xinhua) -- Zimbabwe's newly launched gold-backed currency, known as the Zimbabwe G2024-05-21
atest comment